Clinical trials: Signs and Symptoms, Digestive
Nausea, Vomiting
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)
A multicenter trial to assess the safety and efficacy of an investigational drug in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with confirmed solid tumors who will be treated with a chemotherapy…
- Trial name
- NCT00090207
- Testing
- MK0869, aprepitant / Duration of Treatment: 3 days, Comparator: ondansetron / Duration of Treatment: 4 days
- Volunteers
- 477 people
- Sponsor
- Merck Sharp & Dohme LLC
Short Bowel Syndrome
A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome
The main aim of the study is to assess how well teduglutide works over 24 weeks in Chinese adult participants with short bowel syndrome (SBS) who need parenteral support and to see how much it can reduce the amount of parenteral…
- Trial name
- NCT06973304
- Testing
- Teduglutide
- Where
- 4 sites in China
- Volunteers
- 13 people
- Sponsor
- Takeda
Functional Constipation (FC)
Fiber Nutritional Supplement for Management of Constipation During Pregnancy
This study aims to evaluate the effectiveness of a daily Fiber Nutritional Supplement (Materna® Opti fiber), containing partially hydrolyzed guar gum (PHGG) and vitamins C, D, zinc, and selenium, combined with nutritional…
- Trial name
- NCT07588633
- Testing
- fiber supplement (PHGG) with counselling for constipation management
- Where
- Brazil
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Gastroparesis
Clinical Management With SPM System and Validation of the SPM 5 Hour Cutoff in Patients With Symptoms of Gastroparesis
This protocol is designed to validate use of the SPM for diagnosis of delayed gastric emptying in patients with symptoms of gastroparesis and assess impact of a SmartPill study on patient management in the gastroparetic…
- Trial name
- NCT02022826
- Testing
- SmartPill Monitoring System
- Where
- 11 sites in United States
- Volunteers
- 167 people
- Sponsor
- Medtronic - MITG
Primary Biliary Cholangitis
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
This study will collect information from participants with Primary Biliary Cholangitis (PBC) as they use the drug elafibranor in real world setting.
- Trial name
- ELFINITY (NCT06447168)
- Where
- 72 sites in United States, Australia and 9 more
- Volunteers
- 424 people
- Sponsor
- Ipsen
Constipation
A Safety and Efficacy Evaluation of BLI801 Laxative in Constipated Adults
A pilot study to evaluate the safety and efficacy of multiple BLI801 doses in constipated adults.
- Trial name
- NCT01687985
- Testing
- BLI801 laxative - low dose, BLI801 laxative - high dose
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- Braintree Laboratories
Hepatopathy, Fibrosis
Identification of Biomarkers Related to Liver Fibrosis as New Therapeutic Targets
Fibrosis is a dynamic process resulting from the balance of fibrogenesis and fibrolysis, mainly secondary to chronic necro-inflammation related to regular alcohol consumption, metabolic syndrome (NASH) or viral hepatitis.
- Trial name
- FIBROTHER (NCT03979417)
- Testing
- Blood draw and liver resection
- Where
- 2 sites in France
- Volunteers
- 14 people
- Sponsor
- Institut Pasteur
Neoplasms
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer
- Trial name
- NCT05712889
- Testing
- VIP236 (Q3W), VIP236 (Q2W)
- Where
- 6 sites in United States, Australia
- Volunteers
- 29 people
- Sponsor
- Vincerx Pharma, Inc.
Chronic Hepatitis C
Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II
The purpose of this study is to evaluate the Efficacy, Safety and Pharmacokinetics of Ritonavir-boosted Danoprevir (ASC08) in Combination with Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis…
- Trial name
- NCT03020004
- Testing
- Danoprevir, Ritonavir, peginterferon alfa-2a
- Volunteers
- 70 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Signs and Symptoms, Digestive
Clinical Trial Evaluating the Viability of L. Casei + Fish Oil Capsules
The purpose of this study is to determine the effects of the probiotic KE-99 Lactobacillus casei when administered with omega-3 fish oil on probiotic viability, fecal make-up and gastrointestinal (GI) health in healthy adults.
- Trial name
- Probiomega (NCT01464814)
- Testing
- probiotic plus fish oil capsule, Fish oil capsule
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Nutrition 21, Inc.
Hepatitis C, Chronic
A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection
The purpose of this study is to evaluate the efficacy and safety of TMC435 in combination with peginterferon alfa-2b and ribavirin in chronic genotype 1 hepatitis C virus (HCV)-infected participants who are treatment-naive or…
- Trial name
- NCT01366638
- Testing
- TMC435, Peginterferon alfa-2b (pegIFN alfa-2b), Ribavirin (RBV)
- Where
- 11 sites in Japan
- Volunteers
- 79 people
- Sponsor
- Janssen Pharmaceutical K.K.
Colorectal Neoplasms
Stivarga Regulatory Post-Marketing Surveillance Study in Korea
To investigate and collect post-marketing data on the safety of Stivarga in real world practice in its registered indication(s) as required by Health Authority.
- Trial name
- StivargaPMS (NCT02106858)
- Testing
- Regorafenib (Stivarga,BAY73-4506)
- Where
- South Korea
- Volunteers
- 316 people
- Sponsor
- Bayer
Gastroparesis
The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis
The purpose of this study is to assess the pharmacodynamic effects (gastric emptying), safety, tolerability, and pharmacokinetics of single doses of GSK962040 in Type 1 diabetic patients with gastroparesis.
- Trial name
- NCT00861809
- Testing
- GSK962040 25 mg, GSK962040 50 mg, GSK962040 1250 mg
- Where
- 2 sites in Belgium, Sweden
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Hepatitis C, Chronic
Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)
This is a Phase IIIB, randomized, prospective, multicenter, single-country, open-label, controlled pilot trial designed to evaluate the effect of infliximab induction therapy on sustained virologic response (SVR) to treatment…
- Trial name
- Pegade (NCT00237484)
- Testing
- Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin, Combination of (a) pegylated interferon alfa-2b and (b) ribavirin
- Volunteers
- 89 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis, Chronic Active
CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
The purpose of this study is to determine the efficacy and tolerability of CPG 10101 at two different dose levels with pegylated-interferon-alpha 2B (PEG-IFN) plus ribavirin (RBV) compared to PEG-IFN and RBV without CPG 10101 in…
- Trial name
- NCT00277238
- Testing
- CPG10101, Control
- Where
- 14 sites in United States
- Volunteers
- 113 people
- Sponsor
- Pfizer
Constipation
Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant Pain
The primary purpose of this study is to evaluate the safety and dose-response relationship of N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects administered MOA-728 who have chronic pain…
- Trial name
- NCT00605644
- Testing
- MOA-728
- Volunteers
- 128 people
- Sponsor
- Bausch Health Americas, Inc.
Hepatic Encephalopathy
Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy
This is a global study to compare the effects of AXA1665, an orally active mixture of amino acids, compared to placebo, on cognitive and physical function, as well as the safety and tolerability of AXA1665.
- Trial name
- EMMPOWER (NCT04816916)
- Testing
- AXA1665
- Where
- 40 sites in United States, Canada and 5 more
- Volunteers
- 12 people
- Sponsor
- Axcella Health, Inc
Constipation
Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)
The purpose of this study is to evaluate the safety and efficacy of a range of oral SP-333 doses for the treatment of opioid-induced constipation (OIC) in adults with non-cancer pain taking opioids.
- Trial name
- OIC (NCT01983306)
- Testing
- SP-333 1 mg, SP-333 3 mg, SP-333 6 mg
- Where
- 42 sites in United States
- Volunteers
- 292 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Hepatitis B
The Tolerability and Pharmacokinetics Clinical Trial of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers
Conduct in Chinese healthy adult subjects:1.To observe the safety and tolerability of multiple-dose oral administration of different doses of PNA;2.By measuring the changing drug concentration in the plasma and urine after a…
- Trial name
- NCT03180333
- Testing
- PNA
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Guangzhou Yipinhong Pharmaceutical CO.,LTD
Opioid-induced Constipation
Evaluation of the Quality of Life of Patients With Opioid-induced Constipation Under Treatment With Naloxegol
Opioid-induced constipation (OIC) is a common feature in patients treated with strong opioids. Such medication is often prescribed together with a laxative (osmotic, emollient), with effectiveness depending on the individual…
- Trial name
- KYONAL (NCT04173858)
- Testing
- Naloxegol
- Where
- Spain
- Volunteers
- 126 people
- Sponsor
- Kyowa Kirin Farmacéutica S.L.U.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.